Posters

September 9, 2023

First-in-human phase 1 trial of VT3989, a first-in-class YAP/TEAD inhibitor in patients with advanced mesothelioma

Research and Publications

Publications and Presentations

March 7, 2013

The Hippo Pathway and Human Cancer

Publications and Presentations

November 5, 2015

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

News

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics